Skip to main content

Novorapid & Levemir

Not a lot to report today, so thought I would tell you a bit about the insulins that I take. For those of you who are type I diabetics, this will be dull and you will probably know all about it, but for others, it may be good to see what is involved. Apologies if the picture below makes you feel uneasy, but it shows what an insulin pen looks like.

The needle attached is the smallest they do and is 5mm. The dial on the right is used to select the amount of insulin you want to inject. You then press the button and it clicks until the right dose is selected.

This insulin is called Novorapid. As the name suggests, this is a rapid action that starts working in 10 to 15 minutes. It peaks (as far as I can tell, although opinions on the net vary) in just over an hour and can be in the blood stream for 3-5 hours. I have also read that it can be gone in 2 hours, so am not sure about this figures. Novorapid is taken before meals and means that you can vary the times of your meal and if you want a meal high or low in carbohydrates you can change your dose accordingly. The technical name for this type of insulin is a bolus insulin.

The other insulin that I take is called Levemir. This is taken using a pen that looks the same as the Novorapid, except that it is green. It is an insulin analogue. This means that it is an insulin molecule with another molecule (glargine) attached. Although I can't find the exact mechanism at the moment, it appears the glargine molecule changes the solubility of the insulin. If the insulin doesn't dissolve in the blood stream, it can't be absorbed. The glargine molecule is gradually changed by the blood stream and dissolves leaving the insulin also to dissolve. This takes a number of hours and is gradual. In this way the insulin gets released over time. This is about 24 hours depending on the dose. Levemir is a basal insulin, i.e. it controls your baseline insulin. Lecture over!

Other events of note, was my successful cycle to and from work yesterday. It was hard work and my legs ached at the end, but it seemed to have a positive influence on my blood glucose and also made me feel good in myself! Didn't cycle today as it was throwing it down with rain and I am showing some people around the factory at 19:00 today so wanted to have time to have supper at home and come back.

The training course at work is still ongoing, therefore the buffet leftovers keep appearing. Today, they can't have been hungry as the picture of the left-overs shows:

As my levels were a bit high at lunchtime, I didn't eat any of it. The site secretary however sent me an email to say that she had saved me a couple of cans of Diet Coke as compensation. I was touched!

Finally, Abby wanted to come to work with me today. As it was raining she insisted on putting her wellies on with her dressing gown! Picture below:
Threw a bit of a tantrum when I said she couldn't come. What a confusing world it must be for a toddler, but I love her to bits!



Comments

Popular posts from this blog

Big Announcement - Libre Funding

NEWS RELEASE Embargoed 00:01 November 14 NHS TO PROVIDE LIFE CHANGING GLUCOSE MONITORS FOR TYPE 1 DIABETES PATIENTS Tens of thousands of people with Type 1 diabetes across the country will benefit from life changing glucose monitors on the NHS. To coincide with World Diabetes Day, Simon Stevens, Chief Executive of NHS England, is announcing action to end the current variation patients in some parts of the country are facing to access Freestyle Libre. The wearable sensor does away with the need for inconvenient and sometimes painful finger prick blood tests by relaying glucose levels to a smart phone or e-reader. NHS England will ensure the device, which is the size of a £2 coin and sits on the arm, is available on prescription for all patients who qualify for it in line with NHS clinical guidelines. From April 2019, these patients will be able to receive it on prescription from their local GP or diabetes team helping them to better manage their blood sugar levels. It comes as the NHS seeks t…

Libre - March 2018 Update

Since November 2017 and the official listing of Libre on prescription, so much has changed, but has it changed for the better?

I think broadly the answer to that question is No, but not for want of trying.  The situation has become increasingly confusing and disjointed.

Getting it on Prescription Firstly, the prescribing of Libre.  Wales have said yes, most other areas have said perhaps.  This map shows the current status by CCG: Diabetes UK Joint Policy Tracker.  There are improvements, but this demonstrates the postcode lottery.

The data on prescribing rates are published but this data is woefully slow to become in the public domain.  The final UK country to publish data was Scotland, which finally released December data on 13th March!

Here's the data so far:

This shows an increase, but hardly an avalanche!  Wish I could see the January data...Northern Ireland should publish very soon though.

There are CCGs like Manchester that have now approved prescribing, but it's slow an…

August Libre Update - Data, data and more data!

This month's update will be dealt with in two parts, both focusing on data; the first part summarising some data about the prescribing policies across England, the second my usual update on prescriptions fulfilled across the UK.
Libre Prescribing Policies and Implementation in England There didn't seem to be an easy way to compile this.  I used the Diabetes UK Map to link to the policies and then I cross-checked this with a Google search to see whether there was any more information.  I had to do this line by line for each of the 195 CCGs in England - quite a lengthy and tedious process.  However, I am pleased with the information arising from the data.

Firstly, the headline figures - how many CCGs were funding Libre, how many had denied funding and who were still undecided?  There are differences of opinion about these figures as some CCGs have not been clear (Staffordshire CCGs), and some have agreed to fund, but are yet to actually fund due to implementation difficulties (L…